Delap Wealth Advisory LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 66.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 596 shares of the company’s stock after selling 1,205 shares during the quarter. Delap Wealth Advisory LLC’s holdings in Eli Lilly and Company were worth $540,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of the company. AMJ Financial Wealth Management bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth $201,000. Aveo Capital Partners LLC raised its stake in Eli Lilly and Company by 8.2% during the fourth quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock worth $1,178,000 after acquiring an additional 153 shares in the last quarter. Gryphon Financial Partners LLC boosted its stake in shares of Eli Lilly and Company by 19.4% in the 4th quarter. Gryphon Financial Partners LLC now owns 2,324 shares of the company’s stock valued at $1,355,000 after purchasing an additional 377 shares in the last quarter. Quest Partners LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at approximately $313,000. Finally, Tidemark LLC acquired a new position in Eli Lilly and Company during the 4th quarter worth approximately $29,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.
Eli Lilly and Company Stock Performance
Shares of LLY opened at $921.49 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The firm’s fifty day simple moving average is $895.06 and its two-hundred day simple moving average is $838.32. Eli Lilly and Company has a 12 month low of $516.57 and a 12 month high of $972.53. The stock has a market capitalization of $875.79 billion, a P/E ratio of 135.71, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42.
Eli Lilly and Company Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th were paid a $1.30 dividend. The ex-dividend date was Thursday, August 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.56%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.
Insider Activity at Eli Lilly and Company
In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the sale, the insider now directly owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 442,229 shares of company stock worth $410,002,456 in the last quarter. Company insiders own 0.13% of the company’s stock.
Analyst Ratings Changes
A number of research firms have weighed in on LLY. Guggenheim boosted their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Morgan Stanley reiterated an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Berenberg Bank boosted their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Finally, Jefferies Financial Group raised their price objective on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $977.35.
Read Our Latest Stock Report on Eli Lilly and Company
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read More
- Five stocks we like better than Eli Lilly and Company
- What Investors Need to Know to Beat the Market
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- How Can Investors Benefit From After-Hours Trading
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- The Most Important Warren Buffett Stock for Investors: His Own
- MarketBeat Week in Review – 9/16 – 9/20
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.